Congenica, the global provider of clinical genomics interpretation software, signed a series of significant memorandums of understanding (MOUs) with leading Chinese companies and healthcare providers at a UK-Chinese Future of Medicine trade event in Beijing, China. The meeting was held in conjunction with the State visit of Prime Minister May.
Underlining Congenica’s expansion and potential in China, it was one of only 5 UK companies to attend the signing event held in Beijing. Hosted by UK Secretary of State for International Trade, Dr Liam Fox, and China’s ex-Vice Minister for NHFPC, Jin Xiaotao, each Government set out their vision for the future of digital health and confirmed the opportunities for international collaboration and trade.
The contracts signed by Congenica included:
- An MOU with Digital China Health to include Congenica’s clinical decision support capabilities in the national digital health platform under development in China by Digital China Health.
- An agreement with Unitegen to expand the Chinese market for Sapientia.
The contracts aim to provide innovative solutions that integrate China’s hospital systems and healthcare infrastructure across the country, to efficiently and accurately aggregate and analyze current clinical and genomic data at scale, using Congenica’s gold-standard clinical genomics analysis platform Sapientia™.The series of partnerships with Congenica will help shape Chinese healthcare reform and establish it one of the most advanced in the world.
In June 2017 Congenica announced that the Sapientia platform was being used in a partnership with China-based UniteGen to carry out whole genome sequencing processing and analysis as part of China’s “100K Wellness Pioneer Project”, hosted by Beijing 4P Health Research Institute. BGI Genomics (BGI), a recognized global leader in genomics, has also entered into a commercial contract with Congenica to use Sapientia to support its Chinese operations. In April 2017 Congenica’s Series B fundraising received Chinese investments from BGI as well as Healthlink Capital.
Congenica was represented on the trade mission and at the signing event by its CEO, David Atkins, Ph.D., who is leading the company’s ambitious global expansion plans, including a roll-out of its commercial operations across Europe and the USA as well as in Asia.
- Ends -
Congenica, a leading provider of genomic analysis software and services, has developed the gold-standard clinical genomics analysis platform Sapientia™. Based in Cambridge, UK, and born out of pioneering research from the Sanger Institute, Congenica aims to revolutionize personalized patient care through accurate diagnoses, curation of evolving knowledge bases and support in clinical trials and drug development.
Within a single secured platform, Congenica’s world-class team of experts have gathered together all the resources necessary to enable clinicians and scientists to make informed medical decisions. Validated by Genomics England for the 100K Genomes project, Congenica is empowering doctors around the world to diagnose the un-diagnosable.
Dr Priya Kalia
M +44 (0)7703 769 299 / +46 (0)76 806 85 78